Population-Attributable Fractions of Personal Comorbidities for Liver, Gallbladder, and Bile Duct Cancers
暂无分享,去创建一个
K. Hemminki | A. Försti | J. Sundquist | K. Sundquist | A. Hemminki | Xinjun Li | V. Liska
[1] K. Hemminki,et al. Long‐term survival trends in solid cancers in the Nordic countries marking timing of improvements , 2022, International journal of cancer.
[2] J. Koshiol,et al. Epidemiologic patterns of biliary tract cancer in the United States: 2001–2015 , 2022, BMC Cancer.
[3] K. Hemminki,et al. Personal comorbidities and their subsequent risks for liver, gallbladder and bile duct cancers , 2022, International journal of cancer.
[4] K. Hemminki,et al. Survival trends in solid cancers in the Nordic countries through 50 years. , 2022, European journal of cancer.
[5] K. Hemminki,et al. Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries , 2022, JHEP reports : innovation in hepatology.
[6] K. Hemminki,et al. Long‐term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast? , 2022, International journal of cancer.
[7] K. Hemminki,et al. Familial Risks for Liver, Gallbladder and Bile Duct Cancers and for Their Risk Factors in Sweden, a Low-Incidence Country , 2022, Cancers.
[8] K. Hemminki,et al. Long‐term incidence and survival trends in cancer of the gallbladder and extrahepatic bile ducts in Denmark, Finland, Norway and Sweden with etiological implications related to Thorotrast , 2022, International journal of cancer.
[9] Zhe-yu Chen,et al. Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease , 2022, European Journal of Clinical Pharmacology.
[10] Myeong Jun Song,et al. Advancing the global public health agenda for NAFLD: a consensus statement , 2021, Nature Reviews Gastroenterology & Hepatology.
[11] M. Färkkilä,et al. Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland , 2021, United European gastroenterology journal.
[12] A. Gavin,et al. Comparison of liver cancer incidence and survival by subtypes across seven high‐income countries , 2021, International journal of cancer.
[13] L. Zender,et al. The immunological and metabolic landscape in primary and metastatic liver cancer , 2021, Nature Reviews Cancer.
[14] Darjus F. Tschaharganeh,et al. Liver Inflammation and Hepatobiliary Cancers. , 2021, Trends in cancer.
[15] M. Borad,et al. Aspirin and Statin Use and the Risk of Gallbladder Cancer , 2021, Cancers.
[16] E. Rigopoulou,et al. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases , 2021, Cancers.
[17] A. Zhu,et al. Biliary tract cancer , 2021, The Lancet.
[18] K. Hemminki,et al. Familial risks between Graves disease and Hashimoto thyroiditis and other autoimmune diseases in the population of Sweden , 2020, Journal of translational autoimmunity.
[19] Siddharth Singh,et al. Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis , 2020, Cancers.
[20] B. Isaksson,et al. Treatment patterns and survival in patients with hepatocellular carcinoma in the Swedish national registry SweLiv , 2019, BJS open.
[21] A. Duberg,et al. Hepatitis C Virus Infection and the Temporal Trends in the Risk of Liver Cancer: A National Register-Based Cohort Study in Sweden , 2019, Cancer Epidemiology, Biomarkers & Prevention.
[22] C. Thongprayoon,et al. Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. , 2019, QJM : monthly journal of the Association of Physicians.
[23] R. Sinha,et al. Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies. , 2019, Journal of the National Cancer Institute.
[24] Prashanth Rawla,et al. Epidemiology of gallbladder cancer , 2019, Clinical and experimental hepatology.
[25] A. Villanueva. Hepatocellular Carcinoma. , 2019, The New England journal of medicine.
[26] C. la Vecchia,et al. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors , 2018, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[27] A. Gavin,et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015 , 2018, British Journal of Cancer.
[28] K. Hemminki,et al. Surveillance Bias in Cancer Risk After Unrelated Medical Conditions: Example Urolithiasis , 2017, Scientific Reports.
[29] P. Ott,et al. Time‐trends in incidence and prognosis of hepatocellular carcinoma in Denmark: A nationwide register‐based cohort study , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[30] D. Whiteman,et al. The fractions of cancer attributable to modifiable factors: A global review. , 2016, Cancer epidemiology.
[31] B. Graubard,et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States , 2016, Cancer.
[32] K. Hemminki,et al. Cancer risk in patients with type 2 diabetes mellitus and their relatives , 2015, International journal of cancer.
[33] A. Facciorusso. The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectives. , 2013, Current diabetes reviews.
[34] Hayato Nakagawa,et al. Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. , 2012, World journal of gastroenterology.
[35] A. Toschke,et al. An illustration of and programs estimating attributable fractions in large scale surveys considering multiple risk factors , 2009 .
[36] A. Lindberg,et al. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. , 2006, Respiratory medicine.
[37] J. Zucman‐Rossi,et al. Hepatocellular carcinoma , 1998, Nature Reviews Disease Primers.
[38] O S Miettinen,et al. Proportion of disease caused or prevented by a given exposure, trait or intervention. , 1974, American journal of epidemiology.
[39] S. Taylor-Robinson,et al. Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis. , 2019, Journal of hepatology.